MLB Notebook: Gonzalez says PED test came back negative
VIERA, Fla. — Nationals pitcher Gio Gonzalez says tests for performance-enhancing drugs he was given by Major League Baseball have come back negative.
Gonzalez and other players were listed in a Miami New Times report as receiving performance-enhancing drugs in purported records of a now-closed anti-aging clinic.
Gonzalez said in a brief statement Friday that the players' association informed him that blood and urine tests he was given two days after last month's report came back clean.
He says he expected the negative results and reiterated he has never taken any performance-enhancing drugs.
The Nationals' left-hander didn't take any questions beyond his statement, citing MLB's ongoing investigation into Biogenesis of America LLC.
ESPN reported Tuesday that Gonzalez was the only client named so far who had not received PEDs.
Papelbon says 2012 Phillies lacked leadership
Phillies closer Jonathan Papelbon feels his team lacked leadership last season, and made it known to reporters.
On the day that the Phillies began exhibition play with an intrasquad scrimmage here, Papelbon, who left the Boston Red Sox for Philadelphia in time for last season, reiterated his stance from earlier in the week that says: “Since I've been here, I haven't seen any leadership.”
Santana exhibition debut pushed back
Johan Santana will not make his first spring training appearance for the Mets this year until mid-March.
General manager Sandy Alderson said the 33-year-old left-hander is expected to pitch in an exhibition game sometime from March 10-12 instead of March 2. The two-time AL Cy Young Award winner missed 2011 following shoulder surgery and went 6-9 with a 4.85 ERA in 21 starts last year, when he pitched the first no-hitter in Mets history on June 1 against St. Louis. Rivera throws BP for 1st time since knee injury
Yankees closer Mariano Rivera has thrown batting practice for the first time since knee surgery last year.
The 43-year-old Rivera threw 25 pitches and said he was happy with the results. He expects to be ready when the Yankees open the regular season April 1 against the Boston Red Sox.
Show commenting policy
TribLive commenting policy
You are solely responsible for your comments and by using TribLive.com you agree to our Terms of Service.
We moderate comments. Our goal is to provide substantive commentary for a general readership. By screening submissions, we provide a space where readers can share intelligent and informed commentary that enhances the quality of our news and information.
While most comments will be posted if they are on-topic and not abusive, moderating decisions are subjective. We will make them as carefully and consistently as we can. Because of the volume of reader comments, we cannot review individual moderation decisions with readers.
We value thoughtful comments representing a range of views that make their point quickly and politely. We make an effort to protect discussions from repeated comments either by the same reader or different readers.
We follow the same standards for taste as the daily newspaper. A few things we won't tolerate: personal attacks, obscenity, vulgarity, profanity (including expletives and letters followed by dashes), commercial promotion, impersonations, incoherence, proselytizing and SHOUTING. Don't include URLs to Web sites.
We do not edit comments. They are either approved or deleted. We reserve the right to edit a comment that is quoted or excerpted in an article. In this case, we may fix spelling and punctuation.
We welcome strong opinions and criticism of our work, but we don't want comments to become bogged down with discussions of our policies and we will moderate accordingly.
We appreciate it when readers and people quoted in articles or blog posts point out errors of fact or emphasis and will investigate all assertions. But these suggestions should be sent via e-mail. To avoid distracting other readers, we won't publish comments that suggest a correction. Instead, corrections will be made in a blog post or in an article.
Subscribe today! Click here for our subscription offers.